Identification
NameCarbopol 974P
Accession NumberDB05384
TypeSmall Molecule
GroupsInvestigational
Description

Carbopol 974P is a highly carboxylated polymer composed of lightly cross-linked polyacrylic acid with a broad-spectrum mechanism based on acidification of pathogens. It was under development by ReProtect LLC. It is a gel that may help both block the spread of sexually transmitted diseases and reduce unwanted pregnancies. The compound, known as BufferGel, was in advanced clinical trials for its ability to prevent pregnancy, but was discontinued.

Structure
Thumb
Synonyms
BufferGel
Carbomer 974 (P)
Carbomer 974P
carbomer homopolymer type b
Carbomer homopolymer type B (allyl pentaerythritol crosslinked)
Carbomer-974P
Carbopol polymer
External IDs Not Available
Product Ingredients Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNIIHHT01ZNK31
CAS number151687-96-6
WeightNot Available
Chemical FormulaNot Available
InChI KeyNot Available
InChINot Available
IUPAC NameNot Available
SMILESNot Available
Pharmacology
Indication

Investigated for use/treatment in contraception and HIV prevention.

Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action

BufferGel is a microbicidal spermicide that provides sufficient buffering activity to maintain the mild, protective acidity of the vagina in the presence of semen. Sperm are acid-sensitive, so to assure fertility, semen provides a powerful alkalinizing action that abolishes the protective acidity of the vagina for several hours after intercourse. This alkalinizing action of semen also enables acid-sensitive sexually transmitted diseases (STD) pathogens to transmit infection. By blocking this action of semen, BufferGel prevents unwanted pregnancy, and shows promise for prevention of STDs, including HIV/AIDS.

Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of polyacrylic acid.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of polyacrylic acid.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with polyacrylic acid.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of polyacrylic acid.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of polyacrylic acid.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of polyacrylic acid.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of polyacrylic acid.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with polyacrylic acid.Approved, Investigational
OleandrinAnvirzel may decrease the cardiotoxic activities of polyacrylic acid.Experimental
OuabainOuabain may decrease the cardiotoxic activities of polyacrylic acid.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with polyacrylic acid.Approved, Vet Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of polyacrylic acid.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. van De Wijgert J, Fullem A, Kelly C, Mehendale S, Rugpao S, Kumwenda N, Chirenje Z, Joshi S, Taha T, Padian N, Bollinger R, Nelson K: Phase 1 trial of the topical microbicide BufferGel: safety results from four international sites. J Acquir Immune Defic Syndr. 2001 Jan 1;26(1):21-7. [PubMed:11176265 ]
  2. Tabet SR, Callahan MM, Mauck CK, Gai F, Coletti AS, Profy AT, Moench TR, Soto-Torres LE, Poindexter III AN, Frezieres RG, Walsh TL, Kelly CW, Richardson BA, Van Damme L, Celum CL: Safety and acceptability of penile application of 2 candidate topical microbicides: BufferGel and PRO 2000 Gel: 3 randomized trials in healthy low-risk men and HIV-positive men. J Acquir Immune Defic Syndr. 2003 Aug 1;33(4):476-83. [PubMed:12869836 ]
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections2
2CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections1
2, 3CompletedPreventionPregnancy1
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted PropertiesNot Available
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Taxonomy
ClassificationNot classified
Drug created on November 18, 2007 11:24 / Updated on September 12, 2017 12:35